Skip to content
CSE: XRX.CN 0.16 0.00 0.00%  
XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
    • Metabolic Syndrome / Diabetes
    • Hypertension
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

Reports and Filings

XORTX Financial Statements and MD&A

2018
Q4 Interim Financial Statement

2017

2016

2015

Press Releases

  • XORTX Announces New Clinical Advisory Board Member March 26, 2020
  • XORTX Launches XRx-101 Following the Filing of a Provisional Patent to Potentially Treat Respiratory and Kidney Disease Injury Due to Coronavirus Infection March 16, 2020
  • XORTX Launches XRx-101, A New Program to Treat Coronavirus COVID-19 Infection March 16, 2020
  • XORTX Announces First Tranche Closing of Non-Brokered Private Placement March 2, 2020
  • XORTX Announces Re-Pricing of Private Placement January 31, 2020
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress